---
document_datetime: 2025-06-17 15:56:41
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/noxafil-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: noxafil-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0441233
conversion_datetime: 2025-12-22 20:53:45.023032
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Noxafil

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                             |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------|
| Variation type IB /  | This was an application for a group of | 16/06/2025                          |                                             | SmPC                             | To reduce the approved shelf-life from 36 months to |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000273515                     | variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the SmPC, labelling or package leaflet of human medicinal products in order to adapt to a recommendation of a competent authority , e.g. a Core SmPC, following the assessment of an Urgent Safety Restriction etc. Implementation of wording agreed by the competent authority that require additional minor assessment, e.g. translations are not yet agreed upon. - Accepted B.II.f.1.a Reduction of the shelf life of the finished product - B.II.f.1.a.1 As packaged for sale - Accepted   |            |     |    | 24 months for the 40 mg/ml oral suspension. To replace the tables in SmPC section 5.1 with the reference to the list from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in order to adapt to a recommendation of a competent authority.   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Article 61(3) / EMA/N/0000265304      | - Notification acc. Article 61(3) - Update of the package leaflet with revised contact details of local representatives and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4.                                                                                                                                                                                                                                                                                                                      | 22/04/2025 |     | PL |                                                                                                                                                                                                                                                                     |
| Variation type IA / EMA/VR/0000265704 | B.II.c.3.a From TSE risk material to vegetable or synthetic origin - B.II.c.3.a.1 For excipients or reagents not used in the manufacture of a biological / immunological                                                                                                                                                                                                                                                                                                                                                                                                     | 14/04/2025 | N/A |    |                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| active substance or in a biological / immunological medicinal product - Accepted   |
|------------------------------------------------------------------------------------|